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Cardiovascular disease accounts for nearly 70% of morbidity and mortality in patients with
diabetes mellitus. Strides made in diabetes care have indeed helped prevent or reduce the
burden of microvascular complications in both type 1 and type 2 diabetes. However, the
same cannot be said about macrovascular disease in diabetes. Several prospective trials
so far have failed to provide conclusive evidence of the superiority of glycemic control
in reducing macrovascular complications or death rates in people with advanced disease
or those with long duration of diabetes. There are trends that suggest that beneﬁts are
restricted to those with lesser burden and shorter duration of disease. Furthermore, it
is also suggested that beneﬁts might accrue but it would take a longer time to manifest.
Clinicians are facedwith the challenge to decide how to triage patients for intensiﬁed care vs
less intense care.This review focuses on evidence and attempts to provide a balanced view
of the literature that has radically affected how physicians treat patients with macrovascular
disease. It also takes cognizance of the fact that the natural course of the disease may be
changing aswell, possibly related to better overall awareness and possibly improved access
to information about better individual healthcare.The review further takes note of somehard
held notions about the pathobiology of the disease that must be interpreted with caution in
light of new and emerging data. In light of recent developments ADA and EASD have taken
step to provide some guidance to clinicians through a joint position statement. A lot more
research would be required to ﬁgure out how best to manage macrovascular disease in
diabetes mellitus. Glucocentric stance would need to be reconsidered, and attention paid
to concurrent multifactorial interventions that seem to be effective in reducing vascular
outcomes.
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INTRODUCTION
The prevalence of diabetes is increasing globally mainly through
the increase in the burden of type 2 diabetes. In the United States,
prevalence of diabetes is estimated at 12.9% (Cowie et al., 2009).
For those diagnosed during middle age, diabetes is associated with
10 years of lost life (Narayan et al., 2003). Much of diabetes related
morbidity and mortality relate to cardiovascular disease (CVD;
microvascular and macrovascular), and only through reduction
in these vascular complications, would diabetic patients be able
to achieve a quality (and quantity) of life similar to that enjoyed
by their otherwise healthy counterparts. Patients with diabetes
are at two- to fourfold greater risk for CVD (Kannel and McGee,
1979). This risk persists even after discounting smoking, hyperten-
sion, and dyslipidemia. These observations directly and indirectly
implicate dysglycemia in the residual increased risk of vascular
disease. This, however, should not detract from the cardiovascular
(CV) beneﬁts of blood pressure control and cholesterol lowering
in patients with diabetes mellitus.
HYPERGLYCEMIA AND CARDIOVASCULAR SYSTEM
A complex interaction exists that includes atherogenic dyslipi-
demia (a constellation of high triglycerides, low HDL, and
increase in small dense LDL), chronic kidney disease, and
autonomic dysfunction. A direct acceleration of atherogene-
sis has been attributed to insulin resistance and consequent
hyperglycemia resulting in endothelial dysfunction, activation
of platelets, activation of protein kinase-C, and formation of
advanced glycation end products. Additionally, production of
reactive oxygen species through activation of NF-κB is thought
to be crucial to the development of vascular disease. Two recent
reviews detail most of these mechanisms (Mazzone et al., 2008;
Dandona et al., 2009). Whether steps elucidated in scores of
papers dedicated to atherogenesis in diabetes indeed actually
reﬂect true cause and effect relationship remain to be fully
validated.
EVIDENCE LINKING INCREASED GLUCOSE LEVEL WITH
INCREASED CV-RISKS
Epidemiological evidence supports diabetes as a risk factor for
CVD, and microvascular complications such as nephropathy and
retinopathy. The relation between hyperglycemia and diabetes
has been intensively studied (Coutinho et al., 1999; The Emerg-
ing Risk Factors Collaboration, 2010). Intensive glycemic control
has been suggested to effectively reduce burden of micro and
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macrovascular disease inpeoplewithdiabetes (Stratton et al.,2000;
Adler et al., 2002).
While observational studies generally show a linear relationship
between CVD and elevated glucose, there is possibly a breakpoint
near or below the threshold for diabetes. The atherosclerosis risk
in a community study showed a non-linear relationship to relative
risk of coronary heart disease (CHD) and hemoglobinA1C in non-
diabetic adults (Selvin et al., 2005). An HbA1C level below 4.6%
was not related to CHD risk, but was signiﬁcantly related to risk
above that level.
In about 10,000 individuals without diagnosis of diabetes, the
AusDiab study reported a “J-shaped” relations between CV mor-
tality and fasting glucose besides a continuous increased risk for
CV mortality with increasing HbA1C and 2 h postprandial glucose
during an oral glucose tolerance test (Barr et al., 2009). In an ear-
lier study, Wei et al. (2000) had shown a “U” shaped relationship
with low fasting plasma glucose as predictor of CVD and all-cause
mortality.
The United Kingdom Prospective Diabetes Study (UKPDS)
reported that the relationship between hyperglycemia and CV
mortality is a continuum that starts at glucose level below the
threshold for diagnosis of diabetes. It has been suggested that a
1% decrease in HbA1C should be associated with a 14% decrease
in relative risk for myocardial infarction (MI; Stratton et al., 2000).
Recently, however, analysis of participants in Ludwigshafen
Risk and Cardiovascular Health Study of patients without history
of diabetes undergoing coronary angiography showed a“J” shaped
relationship between glycated hemoglobin, and cardiovascular
and cancer mortality (Silbernagel et al., 2011). In a large cohort
of elderly patients with diabetes (n = 28,000) generated from the
UK General Practice Research Database, a “U” shaped associa-
tion between HbA1C levels and CV events has been suggested
with lowest hazard ratio (HR) at an HbA1C level of approx-
imately 7.5% (Currie et al., 2010). This led to open advocacy
for re-considering the one size ﬁts all, approach in manage-
ment of people with longstanding diabetes drawing customary
ﬁre from the organized specialty societies – coming as close as it
did to the disturbing/surprising results from theAction to Control
Cardiovascular Risk in Diabetes (ACCORD) trial (Mitka, 2010).
GLYCEMIA CONTROL AND CV OUTCOMES
Relationship between glycemia and CV outcomes has been tested
in well-designed interventional trials of intensiﬁed glycemic con-
trol. Four such studies deserve serious consideration (UKPDS
follow-up, ACCORD, ADVANCE, and VADT; Table 1).
The ACCORD Study included 10,251 patients with established
type 2 diabetes, and one-third having had a cardiovascular event
(The Action to Control Cardiovascular Risk in Diabetes Study
Group, 2008). Patients were randomized to intensive glucose con-
trol (targeting an HbA1C < 6.0% and achieving a level of 6.4%)
or standard therapy (targeting HbA1C of 7.0–7.9% and achiev-
ing level of 7.5%). A variety of glucose lowering therapies was
used. There was a non-signiﬁcant trend toward reduction in pri-
mary outcome of trial (a composite of non-fatal MI, non-fatal
stroke, or death from CV causes) with intensive control. However,
unexpectedly there was higher all-cause mortality (HR 1.22, 95%
CI 1.01–1.46, P = 0.04) in the intensive control group. Higher
rates of severe hypoglycemia for subjects in the intensiﬁed con-
trol group were reported. Patients with higher HbA1C at baseline
were at higher risk for hypoglycemia as were those who did not
respond promptly with fall in HbA1C in the intensiﬁed control
group.
The ADVANCE Study was conducted to determine whether
intensive lowering would reduce risk of microvascular and
macrovascular events in individuals with type 2 diabetes and
vascular risk factors-compared to standard conventional care
(The ADVANCE Collaborative Group, 2008). The study involved
11,140 subjects. The mean duration of follow-up was 5 years.
Mean HbA1C achieved was 6.5% in the intensive therapy group
compared with 7.3% in the standard group. Subjects in this
intensive glycemic arm all received modiﬁed-release sulfonylurea
(gliclazide) plus other glucose lowering therapies as needed to
achieve glucose control. The CV component of the primary
endpoint (a component of MI, stroke, and CV death) was not
Table 1 | Clinical characteristics and outcomes of intensive glucose lowering vs standard therapy on primary end point and mortality.
Characteristics ACCORD ADVANCE VADT UKPDS follow-up
n 10,251 11,140 1,791 3,277
Men/women (%) 61/39 58/42 97/3 61/39 (overall)
Mean age (year) 62 66 60 53
Mean duration of diastolic (year) 10 8 11.5 Newly diagnosed
Median HbA1C at entry (%) 8.1 7.2 9.5 7.0
Median HbA1C at study end (%) 6.4 vs 7.5* 6.4 vs 7.0* 6.9 vs 8.4* 7.0 vs 7.9*
Cardiovascular disease (%) 35 32 40 NA
Cardiovascular death (%) ↑ 35 (P = 0.02) ↓ 12 (P = NS) ↑ 25 (P = NS) NA
Any death (%) ↑ 22 (P = 0.04) ↓ 7 (P = NS) ↑ 6.5 (P = NS) NA
Severe hypoglycemia (%) 16.2 vs 5.1* 2.7 vs 1.0* 21.1 vs 9.9* Variable**
*Standard study,
**variable depending on the type of medication.
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signiﬁcantly reduced by intensiﬁed glucose control. The incidence
of combined major and microvascular events was signiﬁcantly
reduced (HR 0.9, 95% CI 0.82–0.98, P = 0.01) in the intensive
glucose control group. This was largely driven by reduction in
progression of albuminuria or emergence of new nephropathy.
There was no evidence of increase in CV or all-cause mortality in
the intensiﬁed control group. Actually there was a non-signiﬁcant
trend toward reduction in all-cause mortality (HR 0.093, 95% CI
0.83–1.06).
The VADT Study included 1,791 American veterans, and
90% were males. A variety of glucose lowering agents was used
including metformin, glimepiride, rosiglitazone, and insulin
(Duckworth et al., 2009). An HbA1C of 6.9% was achieved in
intensiﬁed control arm compared with HbA1C of 8.4% in stan-
dard treatment arm. After a median follow-up of 6.5 years, no
signiﬁcant lowering of composite CV outcomes was noted in the
intensive control group. However, a borderline signiﬁcant reduc-
tion in albuminuria was seen in this group. Beneﬁts of intensive
control were seen in those with shorter duration of diabetes, lower
HbA1C, and absence of CVD at baseline. Coronary calcium scores
predicted higher CV events in those with highest coronary cal-
cium scores. A wide range of coronary calcium scores have been
described in patients with diabetes. Severe hypoglycemiawasmore
prevalent in the intensive control arm.
In the initial UKPDS trial, 3,867 newly diagnosed subjects with
type 2 diabetes were randomized to an intensive glucose control
arm involving use of sulfonylureas or insulin, and a conventional
arm employing lifestyle management. Over the 10-year period of
trial those in the intensiﬁed control arm achieved a mean HbA1C
level of 7.0% compared with mean HbA1C level of 7.9% in con-
trol arm. This degree of intensive control was associated with an
approximately 1% decrease in HbA1C and a non-signiﬁcant 16%
reduction in the risk of MI. There was signiﬁcant reduction in
the risk of microvascular complications (≈25%, 95% CI 7–14,
P = 0.01). There was also a non-signiﬁcant 6% reduction in all-
cause mortality. However, there was no effect of intensive control
or any other CVD outcome. A subgroup of overweight subjects
was included in the study that compared intensive glucose control
with metformin (n = 343) against conventional therapy described
earlier (n = 411). Despite no signiﬁcant difference in HbA1C,
subjects treated with metformin showed a 39% relative risk reduc-
tion (RR) for MI (P = 0.001) and a 36% RR in all-cause mortality
(UK Prospective Diabetes Study (UKPDS) Group, 1998; Holman
et al., 2008).
The UKPDS follow-up study comprised all surviving subjects
that completed the UKPDS randomized intervention trial in 1997.
All subjects returned to usual physician care without any guidance
from UKPDS investigators. Subjects were seen annually for col-
lection of clinical and biochemical data between 1997 and 2001.
Thereafter, between 2002 and 2007 information was gathered
through mailed questionnaires. Over a third of patients who com-
pleted trial in 1997 were followed-up until 2007. Any difference
between HbA1C levels was lost in 1 year following completion of
trial in 1997. In the postintervention follow-upperiod reduction in
microvascular end points weremaintained just like those seen dur-
ing the intervention trial. The beneﬁts of metformin therapy were
also maintained. More interestingly and importantly, the glycemic
control arm showed a signiﬁcant 13% reduction in all-cause mor-
tality and a 15% signiﬁcant reduction in MI. In the metformin
group RR persisted for any diabetes related end point (21%), MI
(33%), and death from any cause (27%). These observations in
patients with type 2 diabetes are similar to those seen in the Dia-
betes Control and Complications Trial (DCCT) follow-up – EDIC
Study (EDIC Research Group, 1999) where difference in reduction
of microvascular complications were maintained despite efface-
ment of differences in HbA1C levels. Furthermore, despite loss of
glycemic separation, CV events, non-fatal MI, stroke, or CV deaths
were reduced by 57% (The Diabetes Control and Complications
Trial/Epidemiology of Diabetes Interventions and Complications
(DCCT/EDIC) Study Research Group, DCCT/EDIC).
These persistent beneﬁts generated from early strict glycemic
control suggest a metabolic memory (also called “legacy effect”)
that outlives original reduction in HbA1C and subsequent loss
of glycemic control. Epigenetic changes have been invoked as a
mechanism to explain legacy effect.
It is worthmentioning that an earlier smaller study (Kumamoto
Study) showed that glycemic control reduces CV events (50%
lower in intensively treated subjects). The absolute number
of events in this study was too low to draw any meaningful
conclusions (Shichiri et al., 2000).
These positive inﬂuences of legacy effect need to be recon-
ciled with unexpected deaths in the ACCORD trial. It seems that
in patients with long standing diabetes and CVD, duration and
magnitude of heart disease adversely affect the outcome if intense
glucose control is forced where lowering of glycemic burden is
difﬁcult to accomplish as reﬂected in failure to affect prompt
reduction in HbA1C. Thus caution is advised in patients with
longer duration of diabetes and higher burden of CVD. On the
other hand those with new onset or short duration of diabetes and
no or lower burden of CVD should receive intensiﬁed glycemic
control. This approach has been incorporated in the joint ADA–
EASD position statement published in April 2012 (Inzucchi et al.,
2012). This is a new direction moving away from hawkish stance
of reducing glycated hemoglobin to less than 7% in all patients.
It takes cognizance of the fact that intensiﬁed glucose control is
fraught with increased risk (twofold increase) of severe hypo-
glycemia. Several meta-analysis have been carried out to sort the
beneﬁts and risks of tighter (intensive) glycemic control. These
have been nicely discussed in a recent publication (Macisaac and
Jerums, 2011). Recently two more meta-analysis have been pub-
lished: the ﬁrst one by Boussageon et al. (2011) found limited
beneﬁts of intensive glucose lowering on all-cause mortality and
deaths from cardiovascular causes, while the second one by Hem-
mingsen et al. (2011) found that intensive glycemic control does
not seem to reduce all-cause mortality in patients with type 2
diabetes, and that available data from randomized clinical trials
remained insufﬁcient to prove or refute relative RR for cardio-
vascular mortality, non-fatal MI, or composite microvascular
complications. Furthermore, intensive glycemic control increased
the relative risk of severe hypoglycemia by 30%.
BOTTOM LINE
Interventional studies have been negative in the sense that
they have failed to convincingly demonstrate the superiority of
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intensiﬁed glycemic control in reducing cardiovascular mortality.
On the plus side, however, these studies have demonstrated that
glucose lowering strategies are safe by and large, and may, over
a period of time offer an advantage. The increased unexplained
mortality seen in the ACCORD trial has dampened any further
enthusiasm until these deaths are totally explained.
Undoubtedly, intensive therapies are associated with a greater
risk of hypoglycemia, and that fear hovers over both the caregivers
and the patients. Several interesting myths seem to have been shat-
tered. (a) That intensiﬁed glucose control alone is sufﬁcient to
tilt the balance favorably in the short run is no longer a tenable
proposition in sicker, older patients and those with long stand-
ing diabetes. (b) That insulin resistance is the major determinant
of vascular disease in patients with diabetes deserves reconsid-
eration. This is evident in many studies where rosiglitazone (an
insulin sensitizer) was associated with more harm (Graham et al.,
2010). Pioglitazone – another insulin sensitizer, fares no better
when it comes to risks of acute MI in elderly patients.
Whether this is a consequence of facilitated insulin action fol-
lowing mitigation of insulin resistance remains to be proved (if
so, it would actually suggest a cardio-protective role for insulin
resistant state – a concept that is alien to current thinking). Fur-
thermore it is important to consider whether modalities employed
to reduce the glycemic load themselves might affect the outcome.
This is particularly true when considering use of sulfonylureas that
have been associated with adverse cardiac outcome (Riddle, 2010).
Insulin resistance as a precursor to evolution of clinical dia-
betes needs to be re-examined in light of unique personal omics
proﬁle just reported (Chen et al., 2012). In this fascinating longi-
tudinal study tracing evolution of diabetes, insulin resistance did
not precede onset of dysglycemia. (c) That intensive lowering of
blood pressure in patients with diabetes should further improve
cardiovascular outcomes also appears to be doubtful as seen in the
ACCORD trial (The ACCORD Study Group, 2010a). (d) That tar-
geting atherogenic dyslipidemia of diabetes using ﬁbrates (↑TG,
↓HDL) may not yield any advantage over use of a statin alone
(The ACCORD Study Group, 2010b).
New approaches are underway to ﬁnd therapies better suited
to favorably affect cardiovascular outcomes. In this regard stud-
ies pertaining to efﬁcacy of “Incretins” and DPP-IV inhibitors as
favorable modulators are being watched with great anticipation.
How Incretins/DPP-IV inhibitors exert favorable effects remains
to be fully sorted out. It is, however, reported that favorable effects
may be linked to enhancement of left ventricular regional func-
tion, and enhancement of delivery of endothelial progenitor cells
(EPCs) under inﬂuence of stromal cell-derived factor (SDF)-1
alpha which mobilizes the EPCs. SDF-1 alpha is a substrate for
DPP-IV, and inhibition of DPP-IV will increase SDF-1 alpha con-
centration. A recent publication addresses cardiovascular effects
of DPP-IV inhibitors in greater depth (Jose and Inzucchi, 2012).
NEW THINKING
Evidence generally trumps intuition, and diabetes care is no excep-
tion. Treatment plans have to be developed to ﬁt the needs and
expectations of the index patient. Sweeping generalizations can
no longer dictate the type and intensity of care. New data that
have emerged in last 5 years should reorient the direction and
thrust of research in diabetes.
FINALLY THE GOOD NEWS
Death rates among both U.S. men and women with diabetes
have declined substantially between 1997 and 2006. This has
reduced the absolute difference between adults with and with-
out diabetes. The rate of improvement among those with diabetes
has exceeded improvement in those without diabetes. Still the
excess mortality risks remain high, but these are signiﬁcantly lower
than before. Contrasting with observations from before, improve-
ments are being noted in both men and women with diabetes
(Gregg et al., 2012).
SUMMARY
Cardiovascular disease in patients with diabetes mellitus remains
one of the leading causes of morbidity and mortality. Attempts
focusing on intensive glucose control to affect the outcomes
remain disappointing thus far. In light of this prudent care would
require cautious multifactorial intervention (Gaede et al., 2008).
Clinicians must use evidence to support implementation of pro-
tocols often used to treat patients with diabetes mellitus outside
of emergencies such as diabetic ketoacidosis and non-ketotic
hyperglycemic-hyperosmolar states. Current evidence supports
individualizing care rather than following a format that does not
allow for individual variation.
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